{"organizations": [], "uuid": "92b6b751040f969e2bfcd424bc78f9a6b7a4a0d8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-diplomat-reaffirms-2017-guidance-p/brief-diplomat-reaffirms-2017-guidance-provides-preliminary-2018-outlook-idUSASB0BZWJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T16:15:00.000+02:00", "replies_count": 0, "uuid": "92b6b751040f969e2bfcd424bc78f9a6b7a4a0d8"}, "author": "", "url": "https://www.reuters.com/article/brief-diplomat-reaffirms-2017-guidance-p/brief-diplomat-reaffirms-2017-guidance-provides-preliminary-2018-outlook-idUSASB0BZWJ", "ord_in_thread": 0, "title": "BRIEF-Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 5, 2018 / 2:15 PM / in 7 minutes BRIEF-Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook Reuters Staff \nJan 5 (Reuters) - Diplomat Pharmacy Inc: \n* - EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE \n* FY2018 EARNINGS PER SHARE VIEW $0.95, REVENUE VIEW $5.38 BILLION -- THOMSON REUTERS I/B/E/S \n* DIPLOMAT REAFFIRMS 2017 GUIDANCE, PROVIDES PRELIMINARY 2018 OUTLOOK * SEES FY 2018 REVENUE UP ABOUT 20 PERCENT * SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION \n* - IN 2018, EXPECTS ADJUSTED EBITDA IN RANGE OF $164 TO $170 MILLION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T16:15:00.000+02:00", "crawled": "2018-01-05T16:33:10.006+02:00", "highlightTitle": ""}